Astragalin

Research use only, not for human use.

Astragalin can be effective in allaying ROS-promoted bronchial fibrosis through inhibiting autophagosome formation in airways.

Astragalin is a flavonoid with anti-inflammatory activity. Astragalin inhibits IL-1β-stimulated nitric oxide and prostaglandin E2 (PGE2) production in patient-derived osteoarthritis chondrocytes. It also inhibits IL-1β-stimulated expression of nitric oxide synthase (NOS) and COX-2 and activation of MAPK and NF-κB signaling. Astragalin also reduces reactive oxygen species (ROS) production, collagen fiber deposition, and autophagosome formation in the epithelial lung tissue of ovalbumin-challenged mice.

Astragalin (0-80 μg/mL; 24 h, 48 h, 72 h) inhibits cancer cells viability and migration at 20, 40, 80 μM, and shows no cytotoxicity to normal human colon epithelial cell lines NCM460.Astragalin (80 μg/mL; 4 h, 8 h) interrupts the NF-κB signaling pathway and inhibits NF-κB P65 transcriptional activity in HCT116 cells stimulated by TNF-α.Astragalin (20, 40, 80 μg/mL; 48 h) induces HCT116 cells apoptosis and arrests cell cycle at G0/G1 phase.Astragalin (20, 40, 80 μg/mL; 48 h) increases the level of apoptin in HCT116 and decreases the level of anti-apoptotic proteins in a dose-dependent manner. Cell Viability Assay Cell Line:Human colon cancer cell lines (HCT116, LoVo, SW620, SW480, Caco2) and human colon epithelial cell lines NCM460 Concentration:0, 5, 10, 20, 40, 80 μg/mL Incubation Time:24, 48, 72 hours Result:Inhibits cancer cells (LoVo, SW620, SW480, Caco2, HCT116) activity at 20, 40, 80 μM. Inhibited HCT116 cells with IC50s of 121.845, 87.908, 18.883 μg/mL at 24, 48, 72 hours, respectively.Showed no cytotoxicity with NCM460 cells.Cell Cycle Analysis Cell Line:Human colon cancer cell HCT116 Concentration:0, 20, 40, 80 μg/mL Incubation Time:48 hours Result:Arrested cell cycle at G0/G1.Western Blot Analysis Cell Line:Human colon cancer cell HCT116 Concentration:80 μg/mL; pre-treated with 20 ng/mL TNF-α Incubation Time:4 or 8 hours Result:Increased the expression of pro-apoptotic proteins (caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, P53, and Bax) and decreased the expression of anti-apoptotic proteins (cleaved caspase-3 and Bcl-2) in a dose-dependent manner.Cell Migration Assay Cell Line:Human colon cancer cell HCT116 Concentration:0, 20, 40, 80 μg/mL Incubation Time:24, 48, 72 hours Result:Reduced release of MMP-2 and MMP-9 enzymes.Inhibited cell migration with mobilities of 14.38, 13.44, and 5.29% with 20, 40, and 80?μg/mL concentrations, respectively.

Astragalin (25, 50, and 75 mg/kg; p.o.; once every two days; 25 d) reduces the tumor volumes, tumor weight and tumor formation rates and decreases expression of p-NFκB and p-iκκα in nude mouse model?with human colon cancer. Animal Model:Male BALB/c nude mice (4-week-old) with HCT116 cells (s.c.)Dosage:0 mg/kg, 25 mg/kg, 50 mg/kg, 75 mg/kg Administration:Oral gavage; once every two days; for 25 days Result:Resulted tumor inhibition rates of 17.43%, 34.89% (p?< 0.01), and 67.06% with 25 mg/kg, 50 mg/kg, 75 mg/kg dose administration.Showed no effect on mouse weight.

Astragalin | Astragaline | K5 | Kaempferol-3-O-glucoside

Others

Other Targets

Others

Inflammation/Immunology

——

480-10-4

448.38

C21H20O11

>98% (HPLC)

DMSO : ≥ 100 mg/mL; 223.03 mM

C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OC4C(C(C(C(O4)CO)O)O)O)O

4H-1-Benzopyran-4-one, 3-(beta-D-glucopyranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-

(-20℃)

With Ice Pack

≥ 2 years